POLICYBZR held its Q2 FY27 earnings call on October 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.
Strong Quarter Across Core Metrics, 14-Quarter Streak Intact
Total insurance premium grew 38% YoY to Rs.9,385 Cr in Q2 FY 2026-2027; management guided to over Rs.40,000 Cr of premium in FY 2026-2027.
Consolidated operating revenue rose 35% YoY to Rs.2,178 Cr, with core insurance revenue up 42% and core credit revenue up 19%; PAT grew 43% YoY to Rs.192 Cr, with PAT margin improving from 8% to 9%.
Core online new Health and Term premium grew 42% YoY (New Health up 46% YoY), with growth led by protection; core new premium (excluding savings) has grown above 34% for 14 consecutive quarters.
Core renewal and trail revenue reached almost Rs.1,100 Cr on a rolling 12-month basis, up 42% YoY; core credit disbursals grew 22% in Q2 FY 2026-2027, rising for five consecutive quarters.
New initiatives (PB Partners, UAE business, PB for Business) delivered Rs.826 Cr revenue, up 40% YoY, and are now close to break even; UAE premium grew 36%. PB Partners revenue was ~Rs.700 Cr in Q2 FY 2026-2027 (actual, per Yashish Dahiya).
Since listing, quarterly revenue has grown from Rs.280 Cr to Rs.2,178 Cr (a 51% CAGR), with PAT margin moving from -73% to 9%.
Management cited ~40% growth for 14 consecutive quarters through Q2 FY 2026-2027, with almost every business outperforming the market by at least 2x and market share gains in every segment.
Regulatory Overhang Dominates — Full Support, But Revenue Impact Acknowledged
Management fully supports IRDAI's stated goals (lower mis-selling, better claims experience, lower prices, deeper penetration) and will implement the final framework fully and in its spirit — but stated that lower distribution payouts will reduce insurance distribution revenue.
Three response fronts are underway: expanding non-insurance revenue as the regulator permits (noted in the discussion paper), accelerating ecosystem offerings, and evaluating other options to strengthen the business over time; more details to be shared when appropriate.
POSP business is under a question mark — Yashish Dahiya said the draft regulation paying open architecture less than closed architecture "does not leave scope for POSP the way it is today"; the company awaits final regulations (timing unspecified), hopes transition time will be provided, and flagged a cash-flow concern as it pays POSPs sooner than insurers pay PB.
Management held multiple meetings with the regulator's chairman to clarify confusion over its POSP vs. core business structure, sharing a health fresh take rate of 24% and motor third-party fresh take rate of 31%; the outcome is a much better understanding of PolicyBazaar's core business.
On dark patterns, PB Fintech and other industry players are engaging with the regulator on whether its customer-number collection flow is a dark pattern; internal analysis is fully done and the company has committed to align fully, but declined to disclose the quantum of business/lead impact, calling it imprudent.
The regulator has received more than 1,000 feedbacks on the discussion paper and will issue draft and final regulations; management is waiting for full clarity before concluding where NPV/IRR implications end up.
Minority stakes in insurers were explicitly ruled out — Yashish Dahiya: "taking minority stakes is not one of them."
Selling & marketing and other expenses rose both QoQ and YoY in Q2 FY 2026-2027; Sarabvir Singh attributed this to very tough demand in FY 2026-2027 forcing higher marketing spend, versus below-normal spend during June-December FY 2025-2026 when demand was robust (linked to the GST impact) — on a two-year basis, the step-up is "not that dramatic."
Management is no longer in the "all-in growth" mode of Q1–Q2 FY 2026-2027 and will be more conscious of the growth-cost balance; previously all priorities (P0-P3) were growth-focused. Yashish Dahiya framed the marginal rule: if marginal NPV falls from X to 0.5X, marginal spend will correspondingly be 0.5X.
Reported capex was up almost 4x YoY (flagged by analyst Ashwin Mehta); Group CFO Mandeep Mehta attributed the increase to expansion of offices, computer infrastructure and staff support as growth ramps up.
Gen AI is a major efficiency lever — over the last 18 months, advisors can now handle 15-20% more leads with improved conversion, better customer service, risk management and faster training; changes will be driven faster over the next 12 to 18 months, though no savings figure was quantified.
October (Q3 FY 2026-2027) hiring was a very small fraction of what it might have been in the past; the POSP business — currently loss-making — is under a question mark, and fixed and variable costs will be revisited once the new NPV framework emerges.
Two commitments the company will not step back from on a "thousand day" perspective: customer propositions (e.g., maternity cover earning zero commission on day one) and the ability to convert and generate inquiries; direct traffic from brand built over 17-18 years continues to drive substantial business.
Management stated the intent is not a cash burn intent, emphasizing NPV is more critical than the cash flow element, with the cash position serving as a capability buffer.
Health Economics Recalibrate; Ecosystem Push Accelerates
PB Health is on track with execution unchanged in Q2 FY 2026-2027 — Alok Bansal guided to a run-rate of Rs.40-50 Cr/month (~Rs.45 Cr) around March 2027, equated to ~Rs.500 Cr for FY 2026-2027; acquired running hospitals are already profit-generating, leaving the business roughly break-even after corporate OPEX and one-two greenfield launches.
Health insurance economics await final commission regulations — Yashish Dahiya said the company will wait before recalibrating health growth; in the current framing, renewals profitability from insurance distribution is extremely limited and fresh payouts are also limited. PB currently performs an estimated 2.5-3.5 of the four activities insurers do (per Sarabvir Singh's framework).
Insurers earn 30-40% ROE through the PB channel (above market ROEs), which management called expecting more from "an unfair expectation"; the incremental cost to an insurer over PB-sourced business is 1-3% at most, excluding claims-ratio benefits from PB-informed underwriting.
Non-insurance offerings are contingent on final regulations — PolicyBazaar will remain insurance-centric ("not a money supermarket, it's an insurance supermarket"); PaisaBazaar is the designated vehicle, but PolicyBazaar will not become a lending platform. Internal teams have begun assessing execution, but management will not act until final regulations are issued (timing unspecified).
PB Pay is a ~3-month-old operation as of the call and is scaling up fast as a payments solution for the insurance industry; no synergy or cost figures were quantified.
Beyond distribution, PB Fintech powers third-party technology backends — the Bahrain government's financial platform is powered by the company; management states there is both the ability and the intention to power more such backends.
PB Health stake will be maintained — neither expanding nor reducing; extending the O&M model to hospitals outside PB Health's balance sheet has no specific plan, with options to be evaluated only from ~18 months out (around FY 2028-2029) after stabilizing 3-5 managed properties.
Flat Sequential Disbursals; Partner Onboarding to Pay Off in Q3
Core disbursals were broadly flat sequentially versus Q1 FY 2026-2027; Santosh Agarwal said the team deliberately avoided aggressive marketing and instead prioritized onboarding new bank/supplier partners and strengthening distribution, expected to play out in Q3 FY 2026-2027.
No change in lending partner behavior from August/September to October 2026 — no underwriting tightening; in fact, some new lending partners have come on board and expanded.
Diversification beyond credit is underway — into bill payments (consumer engagement) and wealth products (bonds, fixed deposits), while Santosh Agarwal cautioned the new lines will take a while to add revenue.
On savings, no discussions with the regulator have occurred that would make savings a larger category; Sarabvir Singh noted PaisaBazaar's wealth stack (mutual funds, bonds, big deposits) creates a multi-product, full-financial-view opportunity — but only "as it gets allowed."
GST Base Effect Fades; Two-Year Growth Rate Framing
The 18% GST reduction drove incremental 18% industry growth in health insurance over the first six months post-cut (a window that has now closed), implying consumer price elasticity for health insurance of ~1 over a six-month time frame.
Management's assessment is that industry Q4 FY 2026-2027 over Q4 FY 2025-2026 may not even be a growth quarter from a new customer acquisition perspective, as the GST impact largely fades by ~March 2027 and the company now faces the reverse of the earlier benefit.
Management asked analysts to evaluate the two-year growth rate, which it believes should stay similar over the next one or two quarters (Q3–Q4 FY 2026-2027); the immediate post-GST period had a short-term impact on PolicyBazaar's visible growth numbers, while renewals of customers who bought immediately post-GST are continuing.
Quality metrics cited vs industry: 97% of PolicyBazaar health claims settled vs 87% industry-wide; 71% of life policies still in force at month 61 vs a benchmark of 51-66% for large players; 16 life insurance complaints per 10,000 customers vs a benchmark of 30-53.
Market reach: about 40% of new retail health customers added across the country come through PolicyBazaar; 17.8% of retail health premium came through the platform in FY 2026-2027; 74% of term and 64% of health policies come from tier 2 and tier 3 cities.
Management's "1,000-day" yardstick: Yashish Dahiya asked stakeholders to judge the company at the end of a 1,000-day period after the day the final regulation comes out (FY timing dependent on when the final regulation is released), stating confidence is "not even half a percent lower than it was 35 days ago."
Multi-year policy economics remain an open question — management declined to respond on whether insurance partners will honor payouts at original sourcing rates or revise them on account of AUM coming in, with the analyst noting PB has aggressively scaled this business.
Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings